Our Mission is to advance science and improve lives faster, together.
Our Vision is to make the most complex protocols easy and accessible to scientists everywhere.
The three Miroculus co-founders — Alejandro Tocigl, Fay Christodoulou, Jorge Soto — met at Singularity University Global Solutions Program in 2013. With their diverse backgrounds, they were drawn together by a shared desire to develop tools that facilitate high quality, advanced scientific research in their home countries. They began working on microRNA for early cancer detection and in the process of developing this technology the trio realized they were building a flexible, intelligent solution for innumerable applications. With Miro Technology Alejandro, Fay and Jorge are realizing their initial vision of making complex protocols easy and accessible to scientists everywhere.
Prior to Miroculus, Alejandro was CEO of MiCoMo, S.A. prior to its acquisition, while also working at Fundación Chile’s venture fund, and was named an MIT Technology Review Innovator Under 35. Alejandro graduated from the Faculty of Economics & Business, Universidad de Chile and completed his B&A studies at the Grand Ecole de Commerce (ESSEC), Paris.
Prior to founding Miroculus, Jorge served as Deputy General Director of Civic Innovation for the country of Mexico, after co-founding CitiVox. Jorge is an Endeavor entrepreneur, World Economic Forum Technology Pioneer, Ashoka Fellow, World Economic Forum Global Shaper and was named an MIT Technology Review Innovator Under 35. He holds a degree in Electrical Engineering from Tec de Monterrey.
Fay’s work has been published in Nature, Cell and Science. In 2012 she was awarded an EU postdoctoral fellowship to investigate the role of microRNAs in thyroid carcinogenesis in the Biomedical Research Foundation of the Academy of Athens, Greece. Following that, she was awarded the 1st prize of the Hellenic Association of Pharmaceutical Companies Innovation Project for her scientific contribution. Fay completed her PhD at the European Molecular Biology Laboratory in Heidelberg, Germany.
Prior to joining Miroculus, Adam was a Partner and Managing Director of Chrysalis Biomedical Advisors. Adam was previously VP of Marketing at Personalis, VP of Commercial Operations at Oxford Nanopore Technologies, and he built and led the product marketing/product management team for next-generation sequencing (NGS) at Illumina. Adam was Director of Scientific Operations at Applied Biosystems (now Thermo Fisher), where he previously held both scientific and commercial roles. He was also Business Development Manager at Agilent Technologies, and was the Product Director and Executive Producer at Genetic Health, a healthcare startup. Adam is a graduate of the Johns Hopkins University.